Circulating matrix Gla protein: A potential tool to identify minor carotid stenosis with calcification in a risk population

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 5, 2013, Pages 1115-1123

  Silaghi, Ciprian N ^a   Fodor, Daniela ^a   Crǎciun, Alexandra M ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

C reactive protein; Calcification; Carotid stenosis; Intima media thickness; Matrix Gla protein

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX GLA PROTEIN; MATRIX PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY DIAMETER; ARTERY INTIMA; ARTICLE; BONE DENSITY; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CORONARY ARTERY CALCIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SERUM; ULTRASOUND;

AGED; BLOOD CHEMICAL ANALYSIS; CALCIUM-BINDING PROTEINS; CAROTID STENOSIS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MIDDLE AGED; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84882278675     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0329     Document Type: Article

References (50)

1. Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag 2009;5:185-97.
2. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006;99:1044-59.
3. Luo G, D ' Souza R, Hogue D, Karsenty G. The matrix Gla protein gene is a marker of the chondrogenesis cell lineage during mouse development. J Bone Miner Res 1995;10:325-34.
4. Wallin R, Cain D, Sane DC. Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells-a cell system which resembles the system in bone cells. Thromb Haemost 1999;82:1764-7.
5. Schurgers LJ, Teunissen KJ, Knapen MH, Kwaijtaal M, van Diest R, Appels A, et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005;25:1629-33.
6. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998-2003.
7. Fraser JD, Price PA. Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. Implications for the possible functions of matrix Gla protein and for the tissue distribution of the gamma-carboxylase. J Biol Chem 1988;263:11033-6.
8. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998;18:1400-7.
9. Zebboudj AF, Imura M, Boström K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002;277:4388-94.
10. Braam LA, Dissel P, Gijsbers BL, Spronk HM, Hamuly á k K, Soute BA, et al. Assay for human matrix gla protein in serum: potential applications in the cardiovascular field. Arterioscler Thromb Vasc Biol 2000;20:1257-61.
11. Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 2010;5:568-75.
12. Thomsen SB, Rathcke CN, Zerahn B, Vestergaard H. Increased levels of the calcification marker matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc Diabetol 2010;9:86.
13. Schurgers LJ, Teunissen KJ, Knapen MH, Geusens P, van der Heijde D, Kwaijtaal M, et al. Characteristics and performance of an immunosorbent assay for human matrix Gla-protein. Clin Chim Acta 2005;351:131-8.
14. Cranenburg EC, Vermeer C, Koos R, Boumans ML, Hackeng TM, Bouwman FG, et al. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res 2008;45:427-36.
15. Rennenberg RJ, de Leeuw PW, Kessels AG, Schurgers LJ, Vermeer C, van Engelshoven JM, et al. Calcium scores and matrix Gla protein levels: association with vitamin K status. Eur J Clin Invest 2010;40:344-9.
16. Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH, Landew é RB, et al. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost 2010;104:811-22.
17. Ueland T, Gullestad L, Dahl CP, Aukrust P, Aakhus S, Solberg OG, et al. Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J Intern Med 2010;268:483-92.
18. Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008;23:3263-71.
19. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004;109:33-8.
20. Prabhakaran S, Singh R, Zhou X, Ramas R, Sacco RL, Rundek T. Presence of calcified carotid plaque predicts vascular events: the Northern Manhattan Study. Atherosclerosis 2007;195: e197-201.
21. Nadareishvili ZG, Rothwell PM, Beletsky V, Pagniello A, Norris JW. Long-term risk of stroke and other vascular events in patients with asymptomatic carotid artery stenosis. Arch Neurol 2002;59:1162-6.
22. Tan YY, Gast GC, van der Schouw YT. Gender differences in risk factors for coronary heart disease. Maturitas 2010;65:149-60.
23. Ness J, Aronow WS. Comparison of prevalence of atherosclerotic vascular disease in postmenopausal women with osteoporosis or osteopenia versus without osteoporosis or osteopenia. Am J Cardiol 2006;97:1427-8.
24. Nandalur KR, Baskurt E, Hagspiel KD, Finch M, Phillips CD, Bollampally SR, et al. Carotid artery calcification on CT may independently predict stroke risk. AJR Am J Roentgenol 2006;186:547-52.
25. Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI, et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis-Society of Radiologists in Ultrasound Consensus Conference. Radiology 2003;229:340-6.
26. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization, 1999.
27. Kanters SD, Algra A, van Leeuwen MS, Banga JD. Reproducibility of in vivo carotid intima-media thickness measurements: a review. Stroke 1997;28:665-71.
28. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129.
29. Haley AP, Forman DE, Poppas A, Hoth KF, Gunstad J, Jefferson AL, et al. Carotid artery intima-media thickness and cognition in cardiovascular disease. Int J Cardiol 2007;121:148-54.
30. Prati P, Vanuzzo D, Casaroli M, Di Chiara A, De Biasi F, Feruglio GA, et al. Prevalence and determinants of carotid atherosclerosis in a general population. Stroke 1992;23:1705-11.
31. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
32. Parker BD, Schurgers LJ, Vermeer C, Schiller NB, Whooley MA, Ix JH. The association of uncarboxylated matrix Gla protein with mitral annular calcification differs by diabetes status: the Heart and Soul study. Atherosclerosis 2010;210:320-5.
33. Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. Herz 2001;26:245-51.
34. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001;89:1147-54.
35. Farzaneh-Far A, Proudfoot D, Weissberg PL, Shanahan CM. Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 2000;277:736-40.
36. Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME. Medial localization of mineralization-regulating proteins in association with M ö nckeberg ' s sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation 1999;100:2168-76.
37. Cancela ML, Hu B, Price PA. Effect of cell density and growth factors on matrix GLA protein expression by normal rat kidney cells. J Cell Physiol 1997;171:125-34.
38. Obata T, Maegawa H, Kashiwagi A, Pillay TS, Kikkawa R. High glucose-induced abnormal epidermal growth factor signaling. J Biochem 1998;123:813-20.
39. Rubin MR, Silverberg SJ. Vascular calcification and osteoporosis-The nature of the nexus. J Clin Endocrinol Metab 2004;89:4243-5.
40. van Summeren MJ, Hameleers JM, Schurgers LJ, Hoeks AP, Uiterwaal CS, Kr üger T, et al. Circulating calcification inhibitors and vascular properties in children after renal transplantation. Pediatr Nephrol 2008;23:985-93.
41. Glagov S, Zarins CK, Masawa N, Xu CP, Bassiouny H, Giddens DP. Mechanical functional role of non-atherosclerotic intimal thickening. Front Med Biol Eng 1993;5:37-43.
42. Beishuizen ED, van de Ree MA, Jukema JW, Tamsma JT, van der Vijver JC, Meinders AE, et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2004;27:2887-92.
43. Henrichs KJ, Unger T, Berecek KH, Ganten D. Is arterial media hypertrophy in spontaneously hypertensive rats a consequence of or a cause for hypertension ? Clin Sci (Lond) 1980;59:331s-3s.
44. Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, Shanahan CM, Vermeer C, et al. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost 2007;5: 2503-11.
45. Kobayashi S, Inoue N, Ohashi Y, Terashima M, Matsui K, Mori T, et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol 2003;23:1398-404.
46. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 2005;166:1265-71.
47. Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, Ungvari Z. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H 2 O 2 , and high intravascular pressure. Circulation 2005;111:2364-72.
48. Abe Y, Sakaguchi M, Furukado S, Okazaki S, Fujinaka T, Sakoda S, et al. Associations of local release of inflammatory biomarkers during carotid artery stenting with plaque echogenicity and calcification. Cerebrovasc Dis 2010; 30:402-9.
49. Bots ML, Hofman A, Grobbee DE. Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis ? Findings from the Rotterdam Study. Stroke 1997;28:2442-7.
50. Horrow MM, Stassi J, Shurman A, Brody JD, Kirby CL, Rosenberg HK. The limitations of carotid sonography: interpretive and technology-related errors. AJR Am J Roentgenol 2000;174:189-94.